Monica Kraft, MD; Reynold A. Panettieri, Jr, MD
This activity is jointly provided by Global Education Group and Integritas Communications.
This activity is supported by an educational grant from AstraZeneca
Monica Kraft, MD
Professor of Medicine
Chair, Department of Medicine
The Robert and Irene Flinn Endowed Chair of Medicine
University of Arizona (UA) College of Medicine - Tucson
Deputy Director, UA Health Sciences Asthma and Airway Disease Research Center
Reynold A. Panettieri, Jr, MD
Professor of Medicine, Robert Wood Johnson Medical School
Vice Chancellor, Translational Medicine and Science
Director, Rutgers Institute for Translational Medicine and Science
Emeritus Professor of Medicine, University of Pennsylvania
Child Health Institute of New Jersey
Rutgers, The State University of New Jersey
New Brunswick, New Jersey
The educational design of this activity addresses the needs of pulmonologists, clinical immunologists, and other specialist clinicians who treat patients with severe asthma.
This Clinical Issues™in Severe Asthma program has been designed to engage and educate attendees while promoting critical thinking. Using a discussion-based format, expert faculty will examine various sides of key clinical issues—including the role of the epithelium in asthma development and progression, mechanisms underlying asthma phenotypes, the rationale for therapies that target disease upstream of the common T2-high and T-low pathways, recent clinical trial evidence for newer pharmacotherapies, and the interpretation and use of biomarkers within management. This program will also expand on attendee engagement by incorporating the clinical experience and unique challenges of the broader asthma community via results from previously deployed learner surveys. In this way, Clinical Issues™ in Severe Asthma intends to deliver not only expert recommendations but learner insights for optimizing severe asthma management across diverse patient populations.
Upon completion of this activity, the participant should be better able to:
- Describe severe asthma pathophysiology, including the upstream role of TSLP and implications for treatment
- Discuss the mechanisms of action and clinical profiles of new targeted therapies for severe asthma, including those targeting TSLP
- Construct treatment regimens for patients with severe asthma with new targeted agents based on symptoms, disease presentation, patient preferences, and shared clinical decision making
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioner Continuing Education
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 1.0 contact hour(s) (which includes 0.2 hour(s) of pharmacology).
Disclosure of Conflicts of Interest
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Monica Kraft, MD - Consulting/Independent Contractor: AstraZeneca plc, Chiesi USA, Inc., Genentech, Inc., Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC; Grants/Research: AstraZeneca plc, Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC; Honoraria: Chiesi USA, Inc.
Reynold A. Panettieri, Jr, MD - Grant/Research Support: ACTIV-1, AstraZeneca plc, Equillium, Inc., Genentech, Inc., Janssen Pharmaceuticals, Inc., MedImmune, LLC, Novartis Pharmaceuticals Corporation, Origo Pharmaceuticals Pvt Ltd, Teva Pharmaceuticals, Vault Health, Inc.; Consultant/Advisory Board: AstraZeneca plc, Bayer AG, Genentech, Inc., Teva Pharmaceutical Industries Ltd.; Speakers Bureau: Merck & Co., Inc., sanofi-aventis U.S. LLC
The planners and managers have the following relevant financial relationships with ineligible companies:
Kristin Delisi, NP: Nothing to disclose
Lindsay Borvansky: Nothing to disclose
Andrea Funk: Nothing to disclose
Liddy Knight: Nothing to disclose
Ashley Cann: Nothing to disclose
Celeste Collazo, MD: Nothing to disclose
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group and Integritas Communications do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Instructions to Receive Credit
In order to receive credit for this activity, the participant must review the activity as well as successfully complete the posttest, by achieving a score of 70% or higher, and evaluation form.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Global Contact Information
For information about the approval of this program, please contact Global at 303-395-1782 or firstname.lastname@example.org.
Click "Begin Activity" to acknowledge that you have reviewed the preamble information for this activity.Begin Activity
credit amount 1.00
credit type CME/AANP
Debates and Discussions About New Upstream Treatment Avenues